Compare QUAD & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUAD | OABI |
|---|---|---|
| Founded | 1971 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.8M | 277.8M |
| IPO Year | 2010 | N/A |
| Metric | QUAD | OABI |
|---|---|---|
| Price | $6.32 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.10 | $6.67 |
| AVG Volume (30 Days) | 123.2K | ★ 418.4K |
| Earning Date | 02-17-2026 | 03-17-2026 |
| Dividend Yield | ★ 4.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,497,700,000.00 | $21,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.20 |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $4.50 | $1.22 |
| 52 Week High | $8.04 | $4.02 |
| Indicator | QUAD | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 36.38 |
| Support Level | $6.08 | $1.64 |
| Resistance Level | $6.38 | $1.86 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 67.27 | 13.98 |
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.